Compare Kinross Gold Corporation (KGC) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinross Gold Corporation vs Medtronic PLC — how do they compare? Kinross Gold Corporation trades at $23.74 (market cap $27.62B), while Medtronic PLC trades at $88.24 (market cap $112.24B). The key difference: Medtronic PLC is far larger — about 4.1× Kinross Gold Corporation's market cap, and Medtronic PLC pays the higher dividend (3.28%). Which is the better fit depends on your goals — on Pluang, investors hold Kinross Gold Corporation for 53 Days and Medtronic PLC for 63 Days on average.
| KGC | MDT | |
|---|---|---|
Market Cap | $27.62B | $112.24B |
Volume | 6,347,266 | 105,663,236 |
Sector | Basic Materials | Health |
52-Week High | $38.06 | $105.35 |
52-Week Low | $22.47 | $73.75 |
Typical Hold Time | 53 Days | 63 Days |
Enterprise Value | $25.70B | $131.58B |
Dividend Yield | 0.69% | 3.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinross Gold (KGC) trades at $23.82, up 2.76% today, but faces a bearish technical signal despite strong fundamentals. The company reported robust earnings, beating estimates for three consecutive quarters, with 2025 revenue of $7.05 billion and net income of $2.39 billion. However, recent news highlights production guidance cuts and legal investigations, creating mixed sentiment. Valuation ratios appear attractive with a P/E of 8.87 and EV/EBITDA of 4.59, while analyst consensus remains bullish with a $38.80 price target.
The outlook for KGC is cautiously optimistic, driven by strong cash flow and gold price resilience, but near-term risks include operational setbacks and legal overhangs. Investment opportunity lies in its undervaluation and shareholder returns, yet investors must weigh production volatility and cost pressures against fundamental strength.
Medtronic (MDT) trades at $87.80, up 2.68% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a 13.93% net income margin and consistent dividend growth over 49 years. Revenue growth accelerated to $33.54B in 2025, and analyst consensus targets $97.80, implying 11% upside. Recent news highlights regulatory approvals for medical devices and a $4B MiniMed exchange offer.
MDT offers value with a 3.2% dividend yield and reasonable valuation (P/E 21.6), but faces headwinds from technical bearishness and rising debt. The stock's appeal hinges on execution of growth initiatives in cardiovascular and neuroscience segments, though competitive and macroeconomic risks persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
